tmem200a Antibody

What is TMEM200A and why is it significant for cancer researchers?

TMEM200A is a member of the transmembrane protein (TMEM) family, which has been identified as significantly overexpressed in several cancer types, most notably gastric cancer (GC). Research indicates that TMEM200A expression is substantially elevated in gastric cancer tissues compared to adjacent normal tissues . Its significance stems from multiple critical findings:

For researchers studying cancer biomarkers, TMEM200A represents a valuable target for understanding tumor progression mechanisms and potentially developing new diagnostic or therapeutic approaches.

Which TMEM200A antibody types are most suitable for different experimental applications?

Based on available research data, researchers should consider the following antibody selection guidelines for TMEM200A detection:

When selecting antibodies, researchers should prioritize those with validation data in their specific application and preferably in gastric cancer or other relevant cancer models. The top validated antibodies according to Antibodypedia include products from Invitrogen, Novus Biologicals, Antibodies.com, and HUABIO Research .

How should TMEM200A antibodies be validated before use in cancer research?

Thorough validation of TMEM200A antibodies is essential for generating reliable research data. A systematic validation approach should include:

• Positive and negative control validation:

  • Positive controls: Use cell lines or tissues known to express TMEM200A (gastric cancer cell lines show reliable expression)

  • Negative controls: Include TMEM200A knockout or knockdown samples as true negative controls

• Cross-reactivity assessment:

  • Test antibody specificity by Western blot to confirm single band of expected molecular weight

  • Compare results with RNA expression data from the same samples to confirm correlation

• Method-specific validation:

  • For IHC: Confirm specificity using peptide competition assays and gradient dilution tests

  • For ICC: Validate subcellular localization consistency with known biology

  • For WB: Verify band size and include loading controls

• Reproducibility testing:

  • Perform technical and biological replicates to ensure consistent results

  • Test different lots of the same antibody when possible

• Knockdown validation:

  • Following the methodology described in research, perform siRNA or shRNA knockdown of TMEM200A to confirm antibody specificity

  • Compare antibody signal in wild-type versus knockdown samples

Proper validation ensures that any observed associations between TMEM200A expression and cancer characteristics are true biological phenomena rather than technical artifacts.

How can researchers effectively use TMEM200A antibodies to study its role in immune infiltration?

TMEM200A has demonstrated significant associations with immune cell infiltration in cancer, particularly gastric cancer. To effectively study this relationship:

• Combined immunohistochemical approach:

  • Use serial tissue sections for IHC with TMEM200A antibodies and immune cell markers

  • Employ multiplexed immunofluorescence to simultaneously detect TMEM200A and multiple immune cell markers

• Flow cytometry applications:

  • Develop protocols combining TMEM200A antibodies with immune cell surface markers

  • Sort cells based on TMEM200A expression for subsequent functional analyses

• Correlation analysis methodology:

  • Following approaches used in published studies, analyze correlations between TMEM200A expression and immune cell infiltration using:

    • TIMER database analysis (as performed in referenced studies)

    • ssGSEA algorithm implementation via the GSVA R package to calculate relationships between TMEM200A and 28 immune cell subtypes

    • Radar plot visualization of correlations between TMEM200A and immune checkpoint/immune cell surface markers

• Functional validation experiments:

  • Use TMEM200A knockdown or overexpression models to assess changes in immune cell recruitment

  • Apply co-culture systems with immune cells and cancer cells with varying TMEM200A expression levels

This systematic approach would allow researchers to both correlate TMEM200A expression with immune infiltration patterns and begin to elucidate mechanistic relationships.

What methodologies should be employed when using TMEM200A antibodies to investigate its role in epithelial-mesenchymal transition (EMT)?

The involvement of TMEM200A in EMT processes represents a significant area of research. To effectively investigate this relationship using TMEM200A antibodies:

• Western blot analysis approach:

  • Develop consistent protocols for simultaneous detection of TMEM200A and key EMT markers (E-cadherin, N-cadherin, vimentin, Snail)

  • Establish reliable protein extraction methods that preserve transmembrane proteins

• TMEM200A knockdown studies:

  • Following methods detailed in research, implement siRNA or shRNA knockdown of TMEM200A in relevant cell models

  • Assess changes in EMT marker expression through Western blot

  • Monitor morphological changes associated with EMT through microscopy

• Signaling pathway investigation:

  • Analyze PI3K/AKT pathway activation in relation to TMEM200A expression

  • Examine phosphorylation status of AKT and related signaling molecules when TMEM200A is modulated

  • Use pathway inhibitors to determine if TMEM200A effects on EMT are mediated through PI3K/AKT

• Immunofluorescence co-localization:

  • Develop co-staining protocols for TMEM200A and EMT markers

  • Analyze subcellular localization changes during EMT induction

• In vitro functional assays:

  • Examine migration and invasion capabilities in relation to TMEM200A expression

  • Correlate functional changes with EMT marker expression

This methodological framework enables researchers to establish not only correlative but also causal relationships between TMEM200A and EMT processes in cancer progression.

How can researchers resolve discrepancies in TMEM200A expression patterns across different cancer types?

The search results indicate varying expression patterns of TMEM200A across cancer types, with upregulation in some cancers and downregulation in others . To address these discrepancies:

• Standardized expression analysis:

  • Use consistent normalization methods when comparing TMEM200A expression across datasets

  • Implement batch effect correction when integrating multiple datasets

  • Account for tissue-specific baseline expression levels

• Cancer subtype differentiation:

  • Stratify analyses by molecular subtypes within each cancer type

  • For gastric cancer specifically, analyze expression differences across Lauren classifications (diffuse vs. intestinal)

  • Consider histological variations when comparing expression patterns

• Technical validation:

  • Verify RNA-seq findings with qPCR on independent cohorts

  • Validate protein expression using multiple antibody clones

  • Compare results across different technical platforms

• Context-specific analysis:

  • Examine TMEM200A expression in relation to:

    • Tumor microenvironment characteristics

    • Stromal content of samples

    • Immune infiltration profiles

• Computational approaches:

  • Implement multivariate analyses to identify confounding factors

  • Use machine learning to identify variables that predict TMEM200A expression

This systematic approach can help resolve apparent contradictions in TMEM200A expression patterns and provide a more nuanced understanding of its context-dependent roles in different cancer types.

What are the methodological considerations when using TMEM200A antibodies for prognostic studies in cancer?

TMEM200A has demonstrated prognostic value in cancer studies, particularly for gastric cancer. When designing prognostic studies using TMEM200A antibodies, researchers should consider:

• Scoring system standardization:

  • Develop and validate quantitative scoring methods for TMEM200A staining intensity

  • Establish threshold values for "high" versus "low" expression based on:

    • Statistical methods (median, ROC curve analysis)

    • Correlation with survival outcomes

    • Comparison with normal tissue expression

• Patient cohort considerations:

  • Ensure adequate sample size with power calculations

  • Include patients across different clinical stages, age groups, and treatment regimens

  • Account for confounding clinical variables (stage, grade, treatment history)

• Statistical analysis methodology:

  • Implement standardized survival analysis approaches:

    • Kaplan-Meier method with log-rank test for initial analysis

    • Cox proportional hazards models for multivariate analysis

    • Nomogram prediction models to integrate TMEM200A with other prognostic factors

• Validation strategies:

  • Include both discovery and validation cohorts

  • Consider different antibody clones to confirm findings

  • Correlate protein expression with RNA expression data when available

• Integration with other biomarkers:

  • Analyze TMEM200A in conjunction with established prognostic markers

  • Consider creating composite prognostic scores

  • Investigate interactions between TMEM200A and immune markers

These methodological considerations ensure that prognostic studies using TMEM200A antibodies generate reliable, clinically relevant results that can potentially inform patient stratification and treatment decisions.

How can researchers optimize protocols for detecting methylation-dependent regulation of TMEM200A?

DNA methylation of TMEM200A has been identified as a potential regulatory mechanism with prognostic implications in cancer . To effectively study this epigenetic regulation:

• Methylation site identification:

  • Utilize the MethSurv database to identify prognostically relevant methylation sites in TMEM200A

  • Validate these sites in independent patient cohorts

  • Correlate methylation patterns with TMEM200A expression levels

• Experimental approaches:

  • Implement bisulfite sequencing for comprehensive methylation analysis

  • Use methylation-specific PCR to target specific sites of interest

  • Apply pyrosequencing for quantitative methylation assessment

• Functional validation:

  • Treat cells with demethylating agents (e.g., 5-azacytidine) and monitor TMEM200A expression changes

  • Perform CRISPR-based epigenetic editing to manipulate methylation at specific TMEM200A sites

  • Correlate methylation changes with functional outcomes (proliferation, migration, etc.)

• Integrative analysis:

  • Combine methylation data with:

    • Transcriptomic profiles

    • Chromatin accessibility data

    • Transcription factor binding information

  • Develop models that predict TMEM200A expression based on methylation patterns

• Clinical correlation:

  • Assess whether TMEM200A methylation status provides additional prognostic information beyond expression levels

  • Investigate the relationship between TMEM200A methylation and treatment responses

This comprehensive approach to studying TMEM200A methylation can provide deeper insights into its regulation and potential clinical applications in cancer diagnostics and treatment.

What are the optimal conditions for using TMEM200A antibodies in quantitative Western blotting?

For consistent and reliable quantitative Western blotting of TMEM200A:

• Sample preparation optimization:

  • Use specialized lysis buffers containing 1-2% SDS or Triton X-100 to effectively solubilize transmembrane proteins

  • Include protease inhibitors to prevent degradation

  • Optimize protein extraction from different tissue types (tumor vs. normal)

• Electrophoresis conditions:

  • Use gradient gels (4-12% or 4-20%) to achieve optimal separation

  • Run at lower voltage (80-100V) to improve resolution of transmembrane proteins

  • Consider specialized gel systems for membrane proteins if standard SDS-PAGE proves challenging

• Transfer parameters:

  • Implement wet transfer systems rather than semi-dry for transmembrane proteins

  • Use lower current (250-300 mA) with longer transfer times (2-3 hours) or overnight at 30V

  • Include methanol in transfer buffer to enhance SDS removal and protein binding to membrane

• Antibody incubation:

  • Based on validated antibody data, use recommended dilutions for primary antibodies (typically 1:500 to 1:2000)

  • Extend primary antibody incubation to overnight at 4°C for optimal signal

  • Include proper blocking with 5% BSA rather than milk (which can interfere with phospho-epitope detection)

• Quantification approach:

  • Use appropriate housekeeping genes as loading controls

  • Implement digital image analysis with dynamic range verification

  • Apply normalization methods appropriate for potentially variable expression of standard housekeeping proteins in cancer samples

Following these optimized conditions will enable researchers to generate consistent and reproducible quantitative data on TMEM200A protein expression.

How can researchers effectively use TMEM200A antibodies in multiplexed immunofluorescence studies?

Multiplexed immunofluorescence offers powerful insights into TMEM200A's relationship with other proteins and cell types in the tumor microenvironment. To optimize this approach:

• Antibody panel design:

  • Select TMEM200A antibodies with minimal species overlap with other targets

  • Validated monoclonal antibodies (e.g., MA5-32881, NBP2-67214) are preferred for multiplexing

  • Consider the following potential panel combinations:

    • TMEM200A + EMT markers (E-cadherin, vimentin)

    • TMEM200A + immune cell markers (CD4, CD8, CD68)

    • TMEM200A + PI3K/AKT pathway components

• Protocol optimization:

  • Test sequential immunostaining with thorough stripping between rounds

  • Alternatively, use directly conjugated primary antibodies with distinct fluorophores

  • Implement tyramide signal amplification for weak signals while preventing cross-reactivity

• Controls and validation:

  • Include single-stained controls for each antibody

  • Use spectral unmixing to address fluorophore overlap

  • Validate staining patterns with serial sections stained with individual antibodies

• Analysis approaches:

  • Implement digital pathology tools for quantitative analysis

  • Measure co-localization indices between TMEM200A and other proteins

  • Analyze spatial relationships between TMEM200A-expressing cells and other cell types

• Data integration:

  • Correlate multiplexed IF findings with other experimental data

  • Develop scoring systems that capture both expression levels and spatial distributions

These approaches enable researchers to generate rich datasets on TMEM200A's relationships with other proteins and cell types within the complex tumor microenvironment.

How can TMEM200A antibodies be utilized in liquid biopsy research?

Exploring TMEM200A detection in liquid biopsies represents an emerging research direction:

• Exosome isolation and analysis:

  • Develop protocols for capturing exosomes from patient plasma or serum

  • Use TMEM200A antibodies to detect protein in exosome preparations via Western blot

  • Quantify TMEM200A-positive exosomes through flow cytometry

• Circulating tumor cell (CTC) detection:

  • Incorporate TMEM200A antibodies into CTC enrichment protocols

  • Develop TMEM200A-based CTC identification systems for gastric and other relevant cancers

  • Correlate TMEM200A-positive CTCs with clinical outcomes

• Method development considerations:

  • Optimize antibody concentration for low-abundance targets in liquid samples

  • Develop signal amplification strategies for enhanced sensitivity

  • Establish reference ranges in healthy controls versus cancer patients

• Clinical correlation studies:

  • Design longitudinal studies tracking TMEM200A in liquid biopsies during treatment

  • Correlate liquid biopsy TMEM200A levels with tissue expression and outcomes

  • Assess liquid biopsy TMEM200A as an early response marker

This emerging application area could potentially translate TMEM200A's prognostic value into minimally invasive monitoring tools for cancer patients.

What is the potential for developing therapeutic antibodies targeting TMEM200A?

Given TMEM200A's association with poor prognosis and potential oncogenic functions , therapeutic targeting represents an intriguing possibility:

• Target validation considerations:

  • Confirm oncogenic dependency through comprehensive knockdown/knockout studies

  • Verify accessibility of TMEM200A epitopes on cancer cell surfaces

  • Identify cancer types most likely to respond to TMEM200A targeting

• Therapeutic antibody design approaches:

  • Engineer antibodies targeting extracellular domains of TMEM200A

  • Consider developing antibody-drug conjugates (ADCs)

  • Explore bispecific antibodies linking TMEM200A with immune effector cells

• Functional screening methods:

  • Develop cell-based assays to screen antibody candidates for:

    • Growth inhibition

    • Apoptosis induction

    • Immune cell recruitment

    • EMT reversal

• Predictive biomarker development:

  • Identify molecular features predicting response to TMEM200A targeting

  • Develop companion diagnostic approaches using existing validated antibodies

  • Establish thresholds for patient selection

While still in early stages, the consistent association of TMEM200A with aggressive cancer features suggests potential for therapeutic development, particularly in gastric cancer where its role is most clearly established.